This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Histone deacetylase 6 (HDAC6)	An <i>in vitro</i> study identified macrocyclic HDAC6 inhibitors that could help treat cancer. <i>In vitro</i> , lead compounds inhibited HDAC6 with low nanomolar IC ₅₀ values and had at least 20-fold selectivity over other HDACs. In lung and colon cancer cell lines, the compounds had low nanomolar cytotoxicity compared with vehicle controls. Next steps include testing HDAC6 inhibitors in combination with cytotoxic chemotherapies. SciBX 3(48); doi:10.1038/scibx.2010.1439 Published online Dec. 16, 2010	Patent application filed; unavailable for licensing	Auzzas, L. <i>et al. J. Med. Chem.</i> ; published online Nov. 12, 2010; doi:10.1021/jm101092u Contact: Stephen Hanessian, University of Montreal, Montreal, Quebec, Canada e-mail: stephen.hanessian@umontreal.ca Contact: Walter Cabri, Sigma-Tau Research and Development, Rome, Italy e-mail: walter.cabri@sigma-tau.it